EU Panel Backs Wider HIV Drug Use for Young Children
The European Medicines Agency's CHMP recommended expanded paediatric indications for ViiV Healthcare's Tivicay and Dovato across the EU.
Updated on Nov. 20, 2026 in Children’s Health

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended expanding the approved uses of ViiV Healthcare's Tivicay and Dovato for younger children living with HIV across the EU. European Commission decisions on the paediatric indications are expected in the first quarter of 2027.
Why it matters
The recommendations target ongoing treatment gaps in paediatric HIV care, where only 55% of children living with HIV globally received antiretroviral therapy in 2024. If approved, they would give clinicians new formulation options for infants and young children.
The new Tivicay dispersible tablet indication covers neonates from birth weighing at least 2kg, while the new Dovato dispersible tablet covers children aged at least three months weighing 6kg to under 25kg. Final European Commission decisions remain pending, expected in Q1 2027.
The players
ViiV Healthcare
ViiV Healthcare is a global HIV-focused pharmaceutical company that develops and markets antiretroviral medicines, including Tivicay and Dovato.
European Medicines Agency (CHMP)
The European Medicines Agency is the EU body responsible for scientific evaluation of medicines, and its Committee for Medicinal Products for Human Use issues opinions on marketing authorizations.
The details
The CHMP recommended extending Tivicay dispersible tablets to HIV-infected adults, adolescents, children and term neonates, and recommended a new Dovato dispersible tablet formulation along with an extension of the film-coated Dovato tablet to children weighing at least 20kg. The recommendations apply when the medicines are used with other antiretroviral medicines.
Timeline
2024: 55% of children living with HIV globally received antiretroviral therapy.
Q1 2027: European Commission decisions on the paediatric indications are expected.
Regulatory Pipeline
These CHMP opinions follow the centralized EU marketing authorization procedure, in which the European Commission issues the legally binding decision after the Agency's scientific review. Final authorization for the paediatric indications is expected in Q1 2027.
If approved, eligible newborns could receive Tivicay, the first second-generation integrase inhibitor available in the EU for that age group. Dovato could become a single-tablet, two-drug option for younger children, potentially simplifying daily treatment routines.
The takeaway
Expanded formulations could reduce the treatment gap for young children with HIV, but final EU authorization is still pending. Families and clinicians should watch for the European Commission decisions expected in early 2027.
What happens next
European Commission decisions on the paediatric indications for Tivicay and Dovato are expected in the first quarter of 2027.
Further reading
For more on treatment access for young patients, see Children's Health.
Source note: This article includes information reported by PharmaTimes.



